[1]Louie J.D., Kothary N., Kuo W.T. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20:606-613.
[2]van den Hoven A.F., Prince J.F., de Keizer B. Use of C-Arm Cone Beam CT During Hepatic Radioembolization : Protocol Optimization for Extrahepatic Shunting and Parenchymal Enhancement. Cardiovasc Intervent Radiol. 2016;39:64-73.
[3]Kallini J.R., Gabr A., Salem R. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33:699-714.
[4]Lewandowski R.J., Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23:64-72.
[5]Vilgrain V., Abdel-Rehim M., Sibert A. Radioembolisation with yttrium90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH) : study protocol for a randomised controlled trial. Trials. 2014;15:474.
[6]Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB : Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018 ; 36 : 1913-1921.
[7]Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol 2017 ; 18 : 1624-1636.
[8]Sangro B., Carpanese L., Cianni R. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54:868-878.
[9]Salem R., Gabr A., Riaz A. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018;68:1429-1440.
[10]Salem R., Lewandowski R.J., Kulik L. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.
[11]Salem R., Gordon A.C., Mouli S. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155-1163.
[12]El Fouly A., Ertle J., El Dorry A. In intermediate stage hepatocellular carcinoma : radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35:627-635.
[13]Lewandowski R.J., Kulik L.M., Riaz A. A comparative analysis of transarterial downstaging for hepatocellular carcinoma : chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
[14]Abouchaleh N., Gabr A., Ali R. (90)Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis : Long-Term Outcomes in a 185-Patient Cohort. J Nucl Med. 2018;59:1042-1048.
[15]Golfieri R., Mosconi C., Cappelli A. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. Future Oncol. 2015;11:3133-3142.
[16]Gulec S.A., Pennington K., Hall M. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment : a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6.
[17]Lewandowski R.J., Donahue L., Chokechanachaisakul A. (90) Y radiation lobectomy : Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114:99-105.
[18]Vouche M., Habib A., Ward T.J. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation : multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192-201.
[19]Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy : Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology 2018 ; 287 : 1050-1058.
[20]Johnson P.J., Berhane S., Kagebayashi C. Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550-558.
[21]Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 2010 ; 138 : 52-64.
[22]Niekamp A., Abdel-Wahab R., Kuban J. Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma. J Clin Med. 2018;7.
[23]Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018 ; 68 : 724-732.
[24]Blanc-Durand P., Van Der Gucht A., Jreige M. Signature of survival: A (18)F-FDG PET based whole-liver radiomic analysis predicts survival after (90)Y-TARE for hepatocellular carcinoma. Oncotarget. 2018;9:4549-4558.